Potential Therapeutic Role of Pituitary Adenylate Cyclase-Activating Polypeptide for Dry Eye Disease
Dry eye disease (DED) is caused by a reduction in the volume or quality of tears. The prevalence of DED is estimated to be 100 million in the developed world. As aging is a risk factor for DED, the prevalence of DED is expected to grow at a rapid pace in aging populations, thus creating an increased...
Main Authors: | Takahiro Hirabayashi, Junko Shibato, Ai Kimura, Michio Yamashita, Fumiko Takenoya, Seiji Shioda |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/2/664 |
Similar Items
-
Presence of Systemic Amyloidosis in Mice with Partial Deficiency in Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Aging
by: Jason Sparks, et al.
Published: (2021-08-01) -
A Broad Overview on Pituitary Adenylate Cyclase-Activating Polypeptide Role in the Eye: Focus on Its Repairing Effect in Cornea
by: Grazia Maugeri, et al.
Published: (2022-01-01) -
Effects of Pituitary Adenylate Cyclase Activating Polypeptide on Cell Death
by: Gabriella Horvath, et al.
Published: (2022-04-01) -
Localization of the neuropeptides pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal peptide, and their receptors in the basal brain blood vessels and trigeminal ganglion of the mouse CNS; an immunohistochemical study
by: Anne Marie Lund, et al.
Published: (2022-10-01) -
Transport of the pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier: implications for migraine
by: Faisal Mohammad Amin, et al.
Published: (2018-05-01)